Evidence map›Paper›PMID 29108283›Full record

ArticleOncotarget2017

Combination of sorafenib and TACE inhibits portal vein invasion for intermediate stage HCC: a single center retrospective controlled study.

Qi Yao, Hongsen Zhang, Bin Xiong, Chuansheng Zheng

Registry-linked trialOpen access · diamondAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Oncotarget, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT05171166 (Neoadjuvant HAIC of TACE Plus Donafenib in BCLC B Stage Hepatocellular Carcinoma Out Up-to-seven), which is not on this map. Cited by 11 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
11citing papers in PubMed, 2 pooled it
1.7field-weighted citation impact, top 15% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT05171166 phase2 / phase3terminatednot on this mapstarted 2021, after this paper: background citation

Neoadjuvant HAIC of TACE Plus Donafenib in BCLC B Stage Hepatocellular Carcinoma Out Up-to-seven: a Multi-center Randomized Controlled Trial.

TypeinterventionalSponsorPeking UniversityRan2021 to 2025Enrolled18ConditionsHepatocellular CarcinomaArmsHAIC, TACE, FOLFOX, cTACE or DEB-TACE, Donafenib
3 · Its place in the literature

Who cites it

11 citing papers in PubMed, 2 syntheses or guidelines pooled it, 16 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Review
  4. Article
  5. Review
  6. Article
  7. Review
  8. Targeted therapy for hepatocellular carcinoma.Signal transduction and targeted therapy · 2020
    Review
  9. Portal Vein Stenting Combined withBioMed research international · 2020
    Article
  10. Article
  11. Intermediate stage hepatocellular carcinoma: a summary review.Journal of hepatocellular carcinoma · 2019
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors at 2 institutions in 1 country.

Qi YaoDepartment of Radiology, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Hubei, China.
Hongsen ZhangDepartment of Radiology, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Hubei, China.
Bin XiongDepartment of Radiology, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Hubei, China.
Chuansheng ZhengDepartment of Radiology, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Hubei, China.
Union Hospital · CNHuazhong University of Science and Technology · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

purposeThis study aims to investigate the effect of sorafenib plus Transarterial Chemoembolization (TACE) treatment on inhibiting portal vein invasion in patients with intermediate stage HCC. MATERIALS AND

methodsThe consecutive medical records of patients with HCC were retrospectively analyzed from October 2009 to February 2015. The propensity score matching method was applied into group matching. The Kaplan-Meier method and the Log-Rank Test was used to estimate the median survival time, median time to progression and median time to portal vein invasion. Factors associated with survival benefits were identified by univariate and multivariate Cox-regression model analyses.

resultsOf 97 patients enrolled, 19 patients received TACE-sorafenib treatment and 78 patients received TACE treatment. During the follow-up period of 15 months, the median time to portal vein invasion was 14.2 months vs 8.77 months, respectively (p=0.073). And the analysis of the cox's proportional hazard model revealed that patients treated with TACE treatment alone would run greater risk of portal vein invasion compared with TACE-sorafenib treatment (hr=7.49, p=0.021). Early administration of sorafenib was associated with lower risk of portal vein invasion (p=0.021) according to the univariate analysis. Adverse events (AEs) identified in the combined group were mostly classified as Grades 1 and 2, and skin-related reactions and fatigue were the most common.

conclusionsSorafenib may could inhibit portal vein invasion of hepatoma carcinoma cells. Early administration of sorafenib may bring more survival benefits.

Indexed as

combined therapyhepatocellular carcinoma (HCC)portal vein invasionsorafenibtranscatheter arterial chemoembolization (TACE)

Identifiers

PMID29108283
PMCPMC5668016
OpenAlexW2753781906

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.